论文部分内容阅读
目的分析注射用核糖核酸联合恩替卡韦治疗乙肝肝硬化的临床效果。方法 60例乙肝肝硬化患者,随机分为对照组和实验组,各30例。对照组患者实施注射用核糖核酸治疗,实验组患者在注射用核糖核酸的基础上实施恩替卡韦治疗,分析比较两组患者的临床疗效及红细胞、白细胞、血小板计数,谷丙转氨酶(ALT)、总胆红素(TBIL)、白蛋白(ALB)及血浆凝血酶原时间(PT)改善情况。结果对照组8例无效,3例有效,12例显效,7例治愈,总有效率为73.33%;实验组2例无效,5例有效,14例显效,9例治愈,总有效率为93.33%;两组患者总有效率比较差异具有统计学意义(P<0.05)。两组患者治疗前红细胞、白细胞、血小板计数、ALT、TBIL、ALB及PT指标比较差异无统计学意义(P>0.05);治疗后红细胞计数、白细胞计数、血小板计数、ALT、TBIL、ALB以及PT指标比较差异具有统计学意义(P<0.05)。结论注射用核糖核酸联合恩替卡韦治疗乙肝肝硬化具有较为显著的临床效果,可有效缓解患者的乏力、纳差、上腹部疼痛等临床症状。
Objective To analyze the clinical effects of injection of ribonucleic acid combined with entecavir in the treatment of hepatitis B cirrhosis. Methods Sixty patients with hepatitis B cirrhosis were randomly divided into control group and experimental group, with 30 cases in each group. Patients in the control group were treated with RNA injection, and patients in the experimental group were treated with entecavir for injection of ribonucleic acid. The clinical efficacy, erythrocytes, white blood cells, platelet count, ALT, (TBIL), albumin (ALB) and plasma prothrombin time (PT) to improve the situation. Results In the control group, 8 cases were ineffective, 3 cases were effective, 12 cases were cured and 7 cases were cured. The total effective rate was 73.33%. In the experimental group, 2 cases were ineffective, 5 cases were effective, 14 cases were cured and 9 cases were cured. The total effective rate was 93.33% There was significant difference between the two groups in the total effective rate (P <0.05). There was no significant difference in erythrocyte, leucocyte, platelet count, ALT, TBIL, ALB and PT before treatment between the two groups (P> 0.05). After treatment, the number of erythrocyte, leucocyte, platelet count, ALT, TBIL, ALB and PT There was significant difference between the indexes (P <0.05). Conclusion Injection of ribonucleic acid combined with entecavir treatment of hepatitis B cirrhosis has a more significant clinical effect, which can effectively alleviate the patient’s fatigue, anorexia, upper abdominal pain and other clinical symptoms.